Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated liposomal doxorubicin + cyclophosphamide + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- CSPC Ouyi Pharmaceutical Group
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of three agents: pegylated liposomal doxorubicin (PLD), cyclophosphamide, and nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Pegylated liposomal doxorubicin is an anthracycline antibiotic encapsulated in pegylated liposomes to reduce cardiotoxicity and prolong circulation time. Cyclophosphamide is an alkylating agent that interferes with DNA replication. Nab-paclitaxel is a taxane microtubule inhibitor formulated as nanoparticles bound to albumin, enhancing delivery and reducing hypersensitivity reactions compared to conventional paclitaxel. This combination has been studied primarily as neoadjuvant therapy for HER2-positive breast cancer, often in conjunction with anti-HER2 agents such as trastuzumab and pertuzumab[1][2][3][4][5]. The regimen aims to maximize antitumor efficacy while minimizing cardiac toxicity associated with traditional anthracyclines.
- Brand names
- Caelyx
- Other names
- PLD + cyclophosphamide + nab-paclitaxelpegylated liposomal doxorubicin + cyclophosphamide + nanoparticle albumin-bound paclitaxel
02
Targets
TOP2A (DNA topoisomerase II)DNA interstrand cross-linkTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pegylated liposomal doxorubicin + cyclophosphamide + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated liposomal doxorubicin + cyclophosphamide + nab-paclitaxel.